

**Sean Marett**  
**Chief Business Officer and Chief Commercial Officer**

<b>Year of Birth</b>	1965
<b>Nationality</b>	British
<b>Management Board Member of BioNTech SE since</b>	2012
<b>End of current appointment</b>	2024
<b>Memberships in statutory Supervisory Boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises</b>	
AiCuris Anti-infective Cures AG, Wuppertal, Germany (not publicly listed Company)	Supervisory Board Member

Sean Marett joined us in 2012. Prior to that, he worked in global strategic and regional marketing and sales roles at GlaxoSmithKline in the United States and Pfizer in Europe, before taking business development executive roles at Evotec and Lorantis, the latter of which he helped to successfully sell to Celldex Therapeutics, Inc. He has successfully executed complex licensing transactions with large pharmaceutical companies, negotiated M&A transactions and raised finance from investors.

Marett built and ran a contract clinical manufacturing organization with operations across Europe and the United States for over half a decade for the contract manufacturer NextPharma. Marett has been Chairman of PHMR Ltd, a company specializing in market access and pharmaceutical reimbursement, since 2017. He previously held non-executive directorship of KWS BioTest Ltd (successfully sold to Charles River) from 2011 until 2018 and was a member of the investment committee of Mann BioInvest Ltd, a fund dedicated to biotechnology and pharmaceutical company investments from 2013 until 2016. He holds a BSc (Hons) in Biochemistry from Kings College London and an MBA from Manchester Business School.